Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
Journal of Antimicrobial Chemotherapy · 03.01.2025 · 80 (1) · 281-291
DOI: 10.1093/jac/dkae407 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 18.11.2024. Verfasst von Kristen Andreatta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA. Hauptthemen laut MEDLINE: Adenine, Alanine, Amides, Anti-HIV Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Objective
Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the efficacy of B/F/TAF was non-inferior to dolutegravir (DTG) + 2 NRTIs. We retrospectively assessed drug adherence and effect on virologic outcomes.
Methods
Studies (NCT02607930, NCT02607956, NCT03547908, NCT02603120 and NCT03110380) were double-blind, placebo-controlled and enrolled treatment-naïve or virologically suppressed adults. Adherence was calculated by pill count from returned pill bottles; virologic outcome was assessed by last on-treatment HIV-1 RNA.
Results
Altogether, 2622 participants (B/F/TAF: n = 1306; DTG + 2 NRTIs: n = 1316) were categorized as having high (≥95%), intermediate (≥85% to <95%) or low (<85%) adherence. Through Week 48, low adherence was observed in 46 (3.5%) participants in the B/F/TAF group (78% median adherence) and 69 (5.2%) in the DTG + 2 NRTI group (80% median adherence). Overall, 1287 (98.5%) participants in the B/F/TAF group and 1292 (98.2%) in the DTG + 2 NRTI group had virologic suppression (VS; HIV-1 RNA < 50 copies/mL) through Week 48. VS in participants with low adherence versus high or intermediate adherence was similar in the B/F/TAF group, but lower in the DTG + 2 NRTI group (P ≤ 0.002). Similar results were observed at Weeks 96 and 144. Two participants (<95% adherence) in the DTG + 2 NRTI group receiving DTG and abacavir/lamivudine developed M184V; there was no treatment-emergent resistance to B/F/TAF.
Conclusions
Participants with suboptimal (<85%) adherence to B/F/TAF maintained high levels of VS, whereas suboptimal DTG + 2 NRTI adherence was associated with lower VS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA.
- Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
- Biostatistics Virology, Gilead Sciences, Inc., Foster City, CA, USA.
- Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Andreatta, K., Sax, P. E., Wohl, D., D'Antoni, M. L., Liu, H., Hindman, J. T., & Callebaut, C. (2025). Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 80(1), 281-291. https://doi.org/10.1093/jac/dkae407
Vancouver
Andreatta K, Sax PE, Wohl D, D'Antoni ML, Liu H, Hindman JT, et al. Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 2025;80(1):281-291. doi:10.1093/jac/dkae407
BibTeX
@article{Andreatta2025,
author = {Andreatta, Kristen and Sax, Paul E and Wohl, David and D'Antoni, Michelle L and Liu, Hui and Hindman, Jason T and Callebaut, Christian},
title = {Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {1},
pages = {281--291},
doi = {10.1093/jac/dkae407}
}
EUVIMED